Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Aspart vs Glibenclamide in Type 2 Diabetes
NCT00267683Phase 3Terminated
- Sponsor
- Novo Nordisk
- Start
- Dec 2005
- Primary completion
- Apr 2006
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of insulin aspart in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Dec 2005; status: terminated.
02
Drugs
insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00267683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00267683.